Apr 17, 2008 by Brian Orelli, PhDFDA and Health Insurers Take On DrugmakersWellPoint provides data to help the FDA find drugs' side effects.
Apr 17, 2008 by Brian Orelli, PhDHeadache Over for Pozen and Glaxo?The duo's FDA headache is over, but a new one is about to begin.
Apr 17, 2008 by Brian Orelli, PhDAbbott's Not AilingAbbott produces double-digit growth; investors yawn.
Apr 16, 2008 by Brian Orelli, PhDJohnson & Johnson Chugs AlongStrong growth, mostly from the weak dollar, fails to excite investors.
Apr 16, 2008 by Brian Orelli, PhDForest Labs' Race Against the ClockInvestors don't like the ambitious plans for research and development. Too bad.
Apr 15, 2008 by Brian Orelli, PhDAffymetrix Misses; Investors PanicBetter days are ahead, but that doesn't seem to matter in today's volatile market.
Apr 14, 2008 by Brian Orelli, PhDStem Cells Show OffThe FDA moves closer to setting up stem cell clinical trials.
Apr 14, 2008 by Brian Orelli, PhDTeva Gets What It WantsTeva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
Apr 11, 2008 by Brian Orelli, PhDSt. Jude's Heartfelt AcquisitionThe medical-device maker picks up tiny EP MedSystems.
Apr 11, 2008 by Brian Orelli, PhDTeva Tugs at Both Ends of the MS StringTeva tries to get multiple sclerosis patients to switch to its drug.
Apr 10, 2008 by Brian Orelli, PhDThe News for Baxter Just Got WorseMore heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company.
Apr 9, 2008 by Brian Orelli, PhDRussia Approves an Unproven TreatmentAntigenics gains approval of Oncophage in Russia.
Apr 9, 2008 by Brian Orelli, PhDRepligen Gets a Surprise Infusion of CashBristol-Myers Squibb agrees to pay Repligen royalties.
Apr 9, 2008 by Brian Orelli, PhDIsis Ignited by Bristol-MyersBristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment.
Apr 8, 2008 by Brian Orelli, PhDSongs of the One-Drug WondersWill these companies become big-name drugmakers or get lost in history?
Apr 8, 2008 by Brian Orelli, PhDKinetic Concepts Grafts On a New DivisionKinetic Concepts buys LifeCell for a premium.
Apr 7, 2008 by Brian Orelli, PhDAbraxis Tries On More Platform ShoesAbraxis buys a platform drug developer.
Apr 3, 2008 by Brian Orelli, PhDMonsanto's Planting Its SeedsStrong growth from the agricultural giant, but will it last?
